Risk of serious cardiovascular problems with medications for attention-deficit hyperactivity disorder

CNS Drugs

Volumn 27, Issue 1, 2013, Pages 15-30

  Martinez Raga, Jose ^a,b,c   Knecht, Carlos ^d   Szerman, Nestor ^e   Martinez, María I ^c  

^a UNIVERSITY OF VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARIO DR PESET   (Spain)

^c UNIVERSIDAD CEU CARDENAL HERRERA   (Spain)

^d Unidad de Salud Mental   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; AMPHETAMINE; ATOMOXETINE; CENTRAL STIMULANT AGENT; CLONIDINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; GUANETHIDINE; GUANFACINE; LISDEXAMFETAMINE; METHAMPHETAMINE; METHYLPHENIDATE; PARACETAMOL; PLACEBO;

ABDOMINAL PAIN; ANOREXIA; ATTENTION DEFICIT DISORDER; BLOOD PRESSURE; BORDERLINE STATE; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONSTIPATION; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DROWSINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; DYSURIA; FATIGUE; GILLES DE LA TOURETTE SYNDROME; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; HYPERTENSION; HYPOTENSION; INSOMNIA; MENTAL DISEASE; MIGRAINE; NAUSEA; ORTHOSTATIC HYPERTENSION; PRIORITY JOURNAL; QT DISPERSION; QT INTERVAL; QT PROLONGATION; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SINUS BRADYCARDIA; SINUS TACHYCARDIA; SOMNOLENCE; SUDDEN DEATH; SUPRAVENTRICULAR TACHYCARDIA; SWEATING; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; TOBACCO DEPENDENCE; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADOLESCENT; ADULT; ANIMALS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEATH, SUDDEN, CARDIAC; HUMANS; LONG QT SYNDROME; RISK FACTORS;

EID: 84873044659     PISSN: 11727047     EISSN: 11791934     Source Type: Journal    
DOI: 10.1007/s40263-012-0019-9     Document Type: Review

References (147)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed, text revision. Washington, DC: American Psychiatric Association; 2000.
2. Biederman J, Faraone SV. Attention-deficit hyperactivity disorder. Lancet. 2005;366:237-48.
3. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-65.
4. Kooij SJ, Bejerot S, Blackwell A, et al. European consensus statement on diagnosis and treatment of adult ADHD: the European Network Adult ADHD. BMC Psychiatry. 2010;10:67.
5. Stein MA. Impairment associated with adult ADHD. CNS Spectr. 2008;13(Suppl. 12):9-11.
6. Sala M, Lazzaretti M, De Vidovich G, et al. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis. 2009;3:29-43.
7. Roden DM. Drug-induced prolongation of the QT interval. N Engl J Med. 2004;350:1013-22.
8. Bradley C. The behavior of children receiving Benzedrine. Am J Psychiatry. 1937;94:577-85.
9. Banaschewski T, Coghill D, Santosh P, et al. Long-acting medications for the hyperkinetic disorders: a systematic review and European treatment guideline. Eur Child Adolesc Psychiatry. 2006;15:476-95.
10. Faraone SV, Glatt SJ. A comparison of the efficacy of medications for adult ADHD using meta-analysis of effect sizes. J Clin Psychiatry. 2010;71:754-63.
11. National Collaborating Centre for Mental Health. Attention deficit hyperactivity disorder: the NICE guideline on diagnosis and management of ADHD in children, young people and adults. National clinical practice guideline number 72. London: Alden Press; 2009.
12. National Institute of Mental Health. National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder. Pediatrics. 2004;113:754-61.
13. Volkow ND, Wang GJ, Fowler JS, et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry. 1998;155:1325-31.
14. Volkow ND, Wang GJ, Fowler JS, et al. Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. Am J Psychiatry. 2004;161:1173-80.
15. Aagaard L, Hansen EH. The occurrence of adverse drug reactions reported for attention deficit hyperactivity disorder (ADHD) medications in the pediatric population: a qualitative review of empirical studies. Neuropsychiatr Dis Treat. 2011;7:729-44.
16. Graham J, Coghill D. Adverse effects of pharmacotherapies for attention-deficit hyperactivity disorder: epidemiology, prevention and management. CNS Drugs. 2008;22:213-37.
17. Findling RL, Biederman J, Wilens TE, et al. Short- and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005;147:348-54.
18. Mick E, McManus DD, Goldberg RJ. Meta-analysis of increased heart rate and blood pressure associated with CNS stimulant treatment of ADHD in adults. Eur Neuropsychopharmacol (epub 2012 Jul 13).
19. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008;17:459-74.
20. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66:253-9.
21. Wilens T, McBurnett K, Stein M, et al. ADHD treatment with once-daily OROS methylphenidate: final results from a long-term open-label study. J Am Acad Child Adolesc Psychiatry. 2005;44:1015-23.
22. Ballard JE, Boileau RA, Sleator EK, et al. Cardiovascular responses of hyperactive children to methylphenidate. JAMA. 1976;236:2870-4.
23. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl). 2003;166:264-70.
24. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009;166:992-1001.
25. Pilgrim JL, Gerostamoulos D, Drummer OH, et al. Involvement of amphetamines in sudden and unexpected death. J Forensic Sci. 2009;54:478-85.
26. Moen MD, Keam SJ. Dexmethylphenidate extended release: a review of its use in the treatment of attention-deficit hyperactivity disorder. CNS Drugs. 2009;23:1057-83.
27. Santosh PJ, Sattar S, Canagaratnam M. Efficacy and tolerability of pharmacotherapies for attention-deficit hyperactivity disorder in adults. CNS Drugs. 2011;25:737-63.
28. Wilens TE, Biederman J, Lerner M, et al. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol. 2004;24:36-41.
29. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59:829-35.
30. Rösler M, Fischer R, Ammer R, Ose C, et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259:120-9.
31. Adler LA, Zimmerman B, Starr HL, et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol. 2009;29:239-47.
32. Adler LA, Orman C, Starr HL, et al. Long-term safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: an open-label, dose-titration, 1-year study. J Clin Psychopharmacol. 2011;31:108-14.
33. Lucas PB, Gardner DL, Wolkowitz OM, et al. Methylphenidate-induced cardiac arrhythmias [letter]. N Engl J Med. 1986;315:1485.
34. Deshmankar BS, Lewis JA. Ventricular tachycardia associated with the administration of methylphenidate during guanethidine therapy. Can Med Assoc J. 1967;97:1166-7.
35. Fernández-Fernández MA, Rufo-Campos M, Mateos-Checa R, et al. Cardiovascular side effects secondary to treatment with methylphenidate [in Spanish]. Rev Neurol. 2010;50:573-4.
36. Nahshoni E, Sclarovsky S, Spitzer S, et al. Early repolarization in young children with attention-deficit/hyperactivity disorder versus normal controls: a retrospective preliminary chart review study. J Child Adolesc Psychopharmacol. 2009;19:731-5.
37. Hill SL, El-Khayat RH, Sandilands EA, et al. Electrocardiographic effects of methylphenidate overdose. Clin Toxicol (Phila). 2010;48:342-6.
38. ®) in a suicidal 14-year-old girl. Atten Defic Hyperact Disord. 2010;2:221-4.
39. Ozdemir E, Karaman MG, Yurteri N, et al. A case of suicide attempt with long-acting methylphenidate (Concerta). Atten Defic Hyperact Disord. 2010;2:103-5.
40. Hammerness P, Wilens T, Mick E, et al. Cardiovascular effects of longer-term, high-dose OROS methylphenidate in adolescents with attention deficit hyperactivity disorder. J Pediatr. 2009;155:84-9.
41. Ruwald MH, Ruwald AC, Tønder N. Methylphenidate induced ST elevation acute myocardial infarction [in Danish]. Ugeskr Laeger. 2012;174:647-8.
42. Stiefel G, Besag FM. Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder. Drug Saf. 2010;33:821-42.
43. Kalant H, Kalant OJ. Death in amphetamine users: causes and rates. Can Med Assoc J. 1975;112:299-304.
44. Lora-Tamayo C, Tena T, Rodríguez A. Amphetamine derivative related deaths. Forensic Sci Int. 1997;85:149-57.
45. Barr AM, Panenka WJ, MacEwan GW, et al. The need for speed: an update on methamphetamine addiction. J Psychiatry Neurosci. 2006;31:301-13.
46. Sylvester AL, Agarwala B. Acute myocardial infarction in a teenager due to Adderall XR. Pediatr Cardiol. 2012;33:155-7.
47. Wilens TE, Spencer TJ, Biederman J. Short- and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr. 2005;10(Suppl. 15):22-30.
48. Donner R, Michaels MA, Ambrosini PJ. Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007;61:706-12.
49. Weisler RH, Biederman J, Spencer TJ, et al. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10:35-43.
50. Cowles BJ. Lisdexamfetamine for treatment of attention-deficit/ hyperactivity disorder. Ann Pharmacother. 2009;43:669-76.
51. Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-27.
52. Elbe D, Macbride A, Reddy D. Focus on lisdexamfetamine: a review of its use in child and adolescent psychiatry. J Can Acad Child Adolesc Psychiatry. 2010;19:303-14.
53. Findling R, Childress A, Cutler A, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395-405.
54. Adler LA, Weisler RH, Goodman DW, et al. Short-term effects of lisdexamfetamine dimesylate on cardiovascular parameters in a 4-week clinical trial in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2009;70:1652-61.
55. Hammerness P, Zusman R, Systrom D, et al. A cardiopulmonary study of lisdexamfetamine in adults with attention-deficit/hyperactivity disorder. World J Biol Psychiatry (epub 2012 May 6).
56. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Pediatr Drugs. 2009;11:203-26.
57. Zerbe RL, Rowe H, Enas GG, et al. Clinical pharmacology of tomoxetine, a potential antidepressant. J Pharmacol Exp Ther. 1985;232:139-43.
58. Michelson D, Faries D, Wernicke J, et al. Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics. 2001;108:E83-91.
59. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53:112-20.
60. Spencer TJ, Biederman J, Wilens TE, et al. Novel treatments for attention-deficit/hyperactivity disorder in children. J Clin Psychiatry. 2002;63(Suppl. 12):16-22.
61. Kratochvil CJ, Milton DR, Vaughan BS, et al. Acute atomoxetine treatment of younger and older children with ADHD: a meta-analysis of tolerability and efficacy. Child Adolesc Psychiatry Ment Health. 2008;2:25.
62. Simpson D, Plosker GL. Atomoxetine: a review of its use in adults with attention deficit hyperactivity disorder. Drugs. 2004;64:205-22.
63. Wernicke JF, Kratochvil CJ. Safety profile of atomoxetine in the treatment of children and adolescents with ADHD. J Clin Psychiatry. 2002;63(Suppl. 12):50-5.
64. Wolraich ML, McGuinn L, Doffing M. Treatment of attention deficit hyperactivity disorder in children and adolescents: safety considerations. Drug Saf. 2007;30:17-26.
65. Trzepacz PT, Williams DW, Feldman PD, et al. CYP2D6 metabolizer status and atomoxetine dosing in children and adolescents with ADHD. Eur Neuropsychopharmacol. 2008;18:79-86.
66. Michelson D, Read HA, Ruff DD, et al. CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. J Am Acad Child Adolesc Psychiatry. 2007;46:242-51.
67. Loghin C, Haber H, Beasley CM, et al. Effects of atomoxetine on the QT interval in healthy CYP2D6 poor metabolizers. Br J Clin Pharmacol (epub 2012 Jul 16).
68. Jefferson JW. A review of the cardiovascular effects and toxicity of tricyclic antidepressants. Psychosom Med. 1975;37:160-79.
69. Wilens TE, Biederman J, Baldessarini RJ, et al. Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry. 1996;35:1491-501.
70. Wernicke JF, Faries D, Girod D, et al. Cardiovascular effects of atomoxetine in children, adolescents, and adults. Drug Saf. 2003;26:729-40.
71. ® (atomoxetine tablets): US prescribing information. Indianapolis: Eli Lilly and Company; 2011.
72. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology. 2008;197:1-11.
73. Wilens TE, Newcorn JH, Kratochvil CJ, et al. Long-term atomoxetine treatment in adolescents with attention-deficit/hyperactivity disorder. J Pediatr. 2006;149:112-9.
74. McCarthy S, Cranswick N, Potts L, et al. Mortality associated with attention-deficit hyperactivity disorder (ADHD) drug treatment: a retrospective cohort study of children, adolescents and young adults using the general practice research database. Drug Saf. 2009;32:1089-96.
75. Dovies M, Cornelius V, Fogg C, et al. A study to examine cardiac events in patients prescribed atomoxetine in England: results of an interim modified prescription event monitoring study. Drug Saf. 2009;32:976-7.
76. Sert A, Gokcen C, Aypar E, et al. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder. Cardiol Young. 2012;22:158-61.
77. Lovecchio F, Kashani J. Isolated atomoxetine (Strattera) ingestions commonly result in toxicity. J Emerg Med. 2006;31:267-8.
78. Spiller HA, Lintner CP, Winter ML. Atomoxetine ingestions in children: a report from poison centers. Ann Pharmacother. 2005;39:1045-8.
79. Stojanovski SD, Robinson RF, Baker SD, et al. Children and adolescent exposures to atomoxetine hydrochloride reported to a poison control center. Clin Toxicol (Philadelphia). 2006;44:243-7.
80. Barker MJ, Benitez JG, Ternullo S, et al. Acute oxcarbazepine and atomoxetine overdose with quetiapine. Vet Hum Toxicol. 2004;46:130-2.
81. Sawant S, Daviss SR. Seizures and prolonged QTc with atomoxetine overdose [letter]. Am J Psychiatry. 2004;161:757.
82. Kashani J, Ruha AM. Isolated atomoxetine overdose resulting in seizure. J Emerg Med. 2007;32:175-8.
83. Scherer D, Hassel D, Bloehs R, et al. Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currents. Br J Pharmacol. 2009;156:226-36.
84. Curran ME, Splawski I, Timothy KW, et al. A molecular basis for cardiac arrhythmia: hERG mutations cause long QT syndrome. Cell. 1995;80:795-803.
85. Wang Q, Chen Q, Towbin JA. Genetics, molecular mechanisms and management of long QT syndrome. Ann Med. 1998;30:58-65.
86. Cohen DJ, Young JG, Nathanson JA, et al. Clonidine in Tourette's syndrome. Lancet. 1979;2(8142):551-3.
87. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38:1551-9.
88. Gourlay S, Forbes A, Marriner T, et al. A placebo-controlled study of three clonidine doses for smoking cessation. Clin Pharmacol Ther. 1994;55:64-9.
89. 2-Adrenergic agonists in opioid withdrawal. Addiction. 2002;97:49-58.
90. Arnsten AF, Scahill L, Findling RL. Alpha-2 adrenergic receptor agonists for the treatment of attention-deficit/hyperactivity disorder: emerging concepts from new data. J Child Adolesc Psychopharmacol. 2007;17:393-406.
91. Connor DF, Findling RL, Kollins SH, et al. Effects of guanfacine extended release on oppositional symptoms in children aged 6-12 years with attention-deficit hyperactivity disorder and oppositional symptoms: a randomized, double-blind, placebo-controlled trial. CNS Drugs. 2010;24:755-68.
92. Ming X, Mulvey M, Mohanty S, et al. Safety and efficacy of clonidine and clonidine extended-release in the treatment of children and adolescents with attention deficit and hyperactivity disorders. AHMT. 2011;2:105-12.
93. Scahill L. Alpha-2 adrenergic agonists in children with inattention, hyperactivity and impulsiveness. CNS Drugs. 2009;23(Suppl. 1):43-9.
94. Cinnamon Bidwell L, Dew RE, Kollins SH. Alpha-2 adrenergic receptors and attention-deficit/hyperactivity disorder. Curr Psychiatry Rep. 2010;12:366-73.
95. Jain AK, Hiremath A, Michael R, et al. Clonidine and guanfacine in hypertension. Clin Pharmacol Ther. 1985;37:271-6.
96. Childress AC, Sallee FR. Revisiting clonidine: an innovative add-on option for attention-deficit/hyperactivity disorder. Drugs Today (Barc). 2012;48:207-17.
97. Jain R, Segal S, Kollins SH, et al. Clonidine extended-release tablets for pediatric patients with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:171-9.
98. Kollins SH, Jain R, Brams M, et al. Clonidine extended-release tablets as add-on therapy to psychostimulants in children and adolescents with ADHD. Pediatrics. 2011;127:e1406-13.
99. Daviss WB, Patel NC, Robb AS, et al. Clonidine for attention-deficit/ hyperactivity disorder: II. ECG changes and adverse events analysis. J Am Acad Child Adolesc Psychiatry. 2008;47:189-98.
100. Fenichel RR. Combining methylphenidate and clonidine: the role of post-marketing surveillance. J Child Adolesc Psychopharmacol. 1995;5:155-6.
101. Maloney MJ, Schwam JS. Clonidine and sudden death. Pediatrics. 1995;96:1176-7.
102. Cantwell DP, Swanson J, Connor DF. Case study: adverse response to clonidine. J Am Acad Child Adolesc Psychiatry. 1997;36:539-44.
103. Schmittner J, Schroeder JR, Epstein DH, et al. QT interval increased after single dose of lofexidine. BMJ. 2004;329:1075.
104. Kofoed L, Tadepalli G, Oesterheld JR, et al. Case series: clonidine has no systematic effects on PR or QTc intervals in children. J Am Acad Child Adolesc Psychiatry. 1999;38:1193-6.
105. Catelli M, Feldman J, Bousquet P, et al. Protective effects of centrally acting sympathomodulatory drugs on myocardial ischemia induced by sympathetic overactivity in rabbits. Braz J Med Biol Res. 2003;36:85-95.
106. Girgis I, Chakko S, de Marchena E, et al. Effect of clonidine on heart rate variability in congestive heart failure. Am J Cardiol. 1998;82:335-7.
107. Biederman J, Melmed RD, Patel A, et al. A randomized, double-blind, placebo-controlled study of guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics. 2008;121:e73-84.
108. Sallee F, McGough J, Wigal T, et al. Guanfacine extended release in children and adolescents with attention-deficit/hyperactivity disorder: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry. 2009;48:155-65.
109. Biederman J, Melmed RD, Patel A, et al. Long-term, open-label extension study of guanfacine extended release in children and adolescents with ADHD. CNS Spectr. 2008;13:1047-55.
110. Spencer TJ, Greenbaum M, Ginsberg LD. Safety and effectiveness of coadministration of guanfacine extended release and psychostimulants in children and adolescents with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol. 2009;19:501-10.
111. Wilens TE, Bukstein O, Brams M, et al. A controlled trial of extended-release guanfacine and psychostimulants for attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:74-85.
112. Bélanger S, Warren A, Hamilton R, et al. Cardiac risk assessment before the use of stimulant medications in children and youth. Paediatr Child Health. 2009;14:579-92.
113. Knight M. Stimulant drug therapy for attention deficit disorder (with or without hyperactivity) and sudden cardiac death. Pediatrics. 2007;119:154-5.
114. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med. 2006;354:1445-8.
115. Villalba L. Follow up review of AERS search identifying cases of sudden death occurring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD), February 28, 2006 (online). http://www.fda.gov/ ohrms/dockets/ac/06/briefing/2006-4210b-07-01-safetyreview.pdf. Accessed 30 May 2011.
116. Berger S, Utech L, Hazinski MF. Sudden death in children and adolescents. Pediatr Clin North Am. 2004;51:1653-77.
117. Cooper WO, Habel LA, Sox CM, et al. ADHD drugs and serious cardiovascular events in children and young adults. N Engl J Med. 2011;365:1896-904.
118. Habel LA, Cooper WO, Sox CM, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. JAMA. 2011;306:2673-83.
119. Schelleman H, Bilker WB, Strom BL, et al. Cardiovascular events and death in children exposed and unexposed to ADHD agents. Pediatrics. 2011;127:1102-10.
120. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/ hyperactivity disorder. Pediatrics. 2007;120:e1494-501.
121. Winterstein AG, Gerhard T, Shuster J, et al. Cardiac safety of methylphenidate versus amphetamine salts in the treatment of ADHD. Pediatrics. 2009;124:e75-80.
122. Olfson M, Huang C, Gerhard T, et al. Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2012;51:147-56.
123. Schelleman H, Bilker WB, Kimmel SE, et al. Methylphenidate and risk of serious cardiovascular events in adults. Am J Psychiatry. 2012;169:178-85.
124. Elia J, Vetter VL. Cardiovascular effects of medications for the treatment of attention-deficit hyperactivity disorder: what is known and how should it influence prescribing in children? Pediatr Drugs. 2010;12:165-75.
125. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP). Elements recommended for inclusion in summaries of product characteristics for methylphenidate-containing medicinal products authorised for the treatment of ADHD in children aged six years and above and adolescents. Wording recommended by the CHMP on 22 January 2009 (online). http://www.ema.europa.eu/docs/en-GB/document-library/Referrals-document/ Methylphenidate-31/WC500011184.pdf. Accessed 18 Mar 2011.
126. Vitiello B, Towbin K. Stimulant treatment of ADHD and risk of sudden death in children. Am J Psychiatry. 2009;166:955-7.
127. Warren AE, Hamilton RM, Bélanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry. Can J Cardiol. 2009;25:625-30.
128. Hamilton R, Gray C, Bélanger SA, et al. Cardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society and the Canadian Academy of Child and Adolescent Psychiatry. J Can Acad Child Adolesc Psychiatry. 2009;18:349-55.
129. Swanson J, Gupta S, Lam A, et al. Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/ hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry. 2003;60:204-11.
130. Silva RR, Skimming JW, Muniz R. Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder. Clin Pediatr (Phila). 2010;49:840-51.
131. Kuehn BM. Stimulant use linked to sudden death in children without heart problems. JAMA. 2009;302:613-4.
132. Hayden GF, Kramer MS, Horwitz RI. The case-control study: a practical review for the clinician. JAMA. 1982;247:326-31.
133. The U.S. Food and Drug Administration. Communication about an ongoing safety review of stimulant medications used in children with attention-deficit/hyperactivity disorder (ADHD), last updated 04/20/2011 (online). http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm165858.htm. Accessed 25 Mar 2011.
134. Westover AN, Halm EA. Do prescription stimulants increase the risk of adverse cardiovascular events? A systematic review. BMC Cardiovasc Disord. 2012;12:41.
135. Vitiello B, Glen R, Elliott GR, et al. Blood pressure and heart rate over 10 years in the Multimodal Treatment Study of children with ADHD. Am J Psychiatry. 2012;169:167-77.
136. Perrin JM, Friedman RA, Knilans TK, et al. Cardiovascular monitoring and stimulant drugs for attention-deficit/hyperactivity disorder. Pediatrics. 2008;122:451-3.
137. Hamilton RM, Rosenthal E, Hulpke-Wette M, et al. Cardiovascular considerations of attention deficit hyperactivity disorder medications: a report of the European Network on Hyperactivity Disorders work group, European Attention Deficit Hyperactivity Disorder Guidelines Group on attention deficit hyperactivity disorder drug safety meeting. Cardiol Young. 2012;22:63-70.
138. Mahle WT, Hebson C, Strieper MJ. Electrocardiographic screening in children with attention-deficit hyperactivity disorder. Am J Cardiol. 2009;104:1296-9.
139. Denchev P, Kaltman JR, Schoenbaum M, et al. Modeled economic evaluation of alternative strategies to reduce sudden cardiac death among children treated for attention deficit/hyperactivity disorder. Circulation. 2010;121:1329-37.
140. Graham J, Banaschewski T, Buitelaar J, et al. European guidelines on managing adverse effects of medication for ADHD. Eur Child Adolesc Psychiatry. 2011;20:17-37.
141. Charach A, Dashti B, Carson P, et al. Attention deficit hyperactivity disorder: effectiveness of treatment in at-risk preschoolers; long-term effectiveness in all ages; and variability in prevalence, diagnosis, and treatment. Comparative effectiveness review no. 44 (prepared by the McMaster University Evidence-based Practice Center under Contract No. MME2202 290-02-0020). AHRQ publication no. 12-EHC003-EF. Rockville (MD): Agency for Healthcare Research and Quality, October 2011 (online). http://www. effectivehealthcare.ahrq.gov/reports/final.cfm. Accessed 29 Oct 2012.
142. Gerhard T, Winterstein AG, Olfson M, et al. Pre-existing cardiovascular conditions and pharmacological treatment of adult ADHD. Pharmacoepidemiol Drug Saf. 2010;19:457-64.
143. Keltikangas-Jarvinen L, Pulkki-Raback L, Puttonen S, et al. Childhood hyperactivity as a predictor of carotid artery intima media thickness over a period of 21 years: the cardiovascular risk in young Finns study. Psychosom Med. 2006;68:509-16.
144. Buchhorn R, Müller C, Willaschek C, et al. How to predict the impact of methylphenidate on cardiovascular risk in children with attention deficit disorder: methylphenidate improves autonomic dysfunction in children with ADHD. ISRN Pharmacol (epub 5 Mar 2012).
145. Mick E, McGough JJ, Middleton FA, et al. Genome-wide association study of blood pressure response to methylphenidate treatment of attention-deficit/ hyperactivity disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2011;35:466-72.
146. Pliszka SR. Pharmacologic treatment of attention-deficit/hyperactivity disorder: efficacy, safety and mechanisms of action. Neuropsychol Rev. 2007;17:61-72.
147. Prasad S, Furr AJ, Zhang S, et al. Baseline values from the electrocardiograms of children and adolescents with ADHD. Child Adolesc Psychiatry Ment Health. 2007;1:11.